ISM0676

ISM3830, An oral, highly selective small molecule CBLB inhibitor ISM0676, an innovative oral small molecule GIPR antagonist ISM5059, an innovative peripherally restricted small molecule NLRP3 inhibitor ISM6166, an innovative oral broad-spectrum pan-KRAS inhibitor ISM001-055 (Rentosertib), a small molecule TNIK inhibitor for treating idiopathic pulmonary fibrosis (IPF). The Phase IIa GENESIS-IPF study demonstrated strong safety and tolerability, with a dose-dependent improvement in lung function. This represents the first clinical proof-of-concept for an AI-discovered drug. ISM5411 (Garutadustat), a gut-restricted small molecule PHD1/2 inhibitor for inflammatory bowel disease (IBD) treatment. A Phase IIa clinical study named BETHESDA was launched, where first patient dosing was completed. ISM6331, a non-covalent small molecule pan-TEAD inhibitor for solid tumor treatment. Preclinical data showed broad-spectrum anti-tumor activity at low doses with favorable safety. Global multicenter Phase I trial initiated with first patient dosed. ISM3412, a small molecule MAT2A inhibitor for MTAP-deleted tumor treatment; preclinical studies demonstrated ideal efficacy, selectivity, druggability and combination potential. Initiated global multicenter Phase I trial and completed first patient dosing. ISM001-055 (Rentosertib)-Inhalation, an inhalable formulation of the TNIK inhibitor for treating idiopathic pulmonary fibrosis. Features potential advantages of high technical barriers, low efficacious dose, large safety window, and minimal side effects. IND application has been submitted for clinical trial.